Introduction: Salvage lymph node dissection (sLND) has been proposed as a treatment option for prostate cancer patients with lymph node (LN) recurrence following radical prostatectomy to delay or avoid palliative androgen deprivation therapy (ADT).
Barcelona, Spain (UroToday.com) Dr. Viktor Grunwald provided a discussion of two abstracts at the ESMO 2019 annual congress poster discussion: 911PD – A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced Renal Cell Carcinoma (RCC), and 912PD – Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 […]
Barcelona, Spain (UroToday.com) Dr. Viktor Grunwald provided a discussion of two abstracts at the ESMO 2019 annual congress poster discussion: 911PD – A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced Renal Cell Carcinoma (RCC), and 912PD – Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 […]
Barcelona, Spain (UroToday.com) Sarcomatoid differentiation can occur in all subtypes of renal cell carcinoma (RCC) and is associated with an aggressive phenotype. Sarcomatoid RCC (sRCC) is characterized by immunologic infiltration and has with higher PD-1/PD-L1 on tumor cells and tumor-infiltrating immune cells. JAVELIN Renal 101 demonstrated a significant improvement in progression-free survival (PFS) with avelumab plus […]
Barcelona, Spain (UroToday.com) Taxanes (docetaxel, cabazitaxel) and androgen receptor-targeted therapies (ARTs; abiraterone, enzalutamide) are standard of care in metastatic castration resistant prostate cancer (mCRPC). However, patients may not respond to abiraterone after progressing on prior enzalutamide or vice versa. Cabazitaxel retains activity in patients progressing on prior docetaxel, abiraterone, or enzalutamide. Importantly, the optimal treatment sequence […]
Barcelona, Spain (UroToday.com) First-line metastatic urothelial carcinoma treatment includes cisplatin or carboplatin-based chemotherapy or checkpoint inhibitors, depending on patient eligibility and PD-L1 status. Approximately 50% of patients are platinum ineligible and they may receive inferior carboplatin-based regimens. In July 2018, the FDA and EMA revised the first-line label for atezolizumab and pembrolizumab based on IMDC assessments. […]
Barcelona, Spain (UroToday.com) Approximately 20% of seminoma germ cell tumors (GCTs) have an elevated level of serum HCG at the time of first diagnosis. The prognostic role of different HCG marker levels is not clear. In this abstract, the authors sought to evaluate the prognostic impact of elevated HCG levels at first diagnosis. Patients included […]
Barcelona, Spain (UroToday.com) Cisplatin based chemotherapy has been the standard of care first line therapy for metastatic urothelial carcinoma (mUC) for several decades. However, up to 50% of patients may not be medically eligible for cisplatin chemotherapy, and so efficacious alternative first line regimens are required. Based on phase 2 data, the FDA has approved both […]
Barcelona, Spain (UroToday.com) Following oral presentation of the PROfound study of olaparib in metastatic castration-resistant prostate cancer (mCRPC) patients with selected homologous recombination repair defects in their tumors, Dr. Eleni Efstathiou discussed the findings and posed the question of whether this study should be considered practice-changing. The discussant outlined her requirements for a study to be […]
Barcelona, Spain (UroToday.com) Despite significant progress in systematic therapy metastatic castration-resistant prostate cancer (mCRPC) continues to be a lethal disease. mCRPC is molecularly heterogeneous, as up to 30% of mCRPC harbor deleterious alterations in DNA damage repair genes, including those with direct and indirect roles in homologous recombination repair. These loss-of-function alterations in homologous recombination […]
